Treatment-resistant depression: Response to low-dose transdermal but not oral selegiline [10]

Journal of Clinical Psychopharmacology

Volumn 27, Issue 3, 2007, Pages 313-314

  Morgan, Peter T ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CLONAZEPAM; ESCITALOPRAM; FLUOXETINE; LITHIUM; OLANZAPINE; SELEGILINE; ZOLPIDEM;

AGED; ANAMNESIS; APPLICATION SITE IRRITATION; CASE REPORT; CLINICAL FEATURE; CONSTIPATION; DRUG DOSAGE FORM COMPARISON; DRUG WITHDRAWAL; FLUID INTAKE; HUMAN; LETTER; LOW DRUG DOSE; MAJOR DEPRESSION; MALE; MEDICAL EXAMINATION; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, CUTANEOUS; AGED; DEPRESSION; DRUG ADMINISTRATION ROUTES; DRUG RESISTANCE; HUMANS; MALE; MONOAMINE OXIDASE INHIBITORS; SELEGILINE;

EID: 34248589704     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000270085.15253.15     Document Type: Letter

References (9)

1. Sunderland T, Cohen RM, Molchan S, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry. 1994;51:607-615.
2. White K, Razani J, Cadow B, et al. Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial. Psychopharmacology (Berl). 1984;82:258-262.
3. Robinson DS, Nies A, Ravaris CL, et al. The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive-anxiety states. A controlled clinical trial. Arch Gen Psychiatry. 1973;29:407-413.
4. Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl. 1993:30-34.
5. Lipper S, Murphy DL, Slater S, et al. Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology (Berl). 1979;62:123-128.
6. Patkar AA, Pae CU, Masand PS. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006;11:363-375.
7. Higuchi H, Kamata M, Sugawara Y, et al. Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report. Clin Neuropharmacol. 2005;28:191-192.
8. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002;159:1869-1875.
9. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003; 64:208-214.